Simeprevir is a NS3/4A protease inhibitor and a number of presentations on its efficacy will be reported at the conference. Early-stage data on the investigational nucleotide analog polymerase inhibitors AL-335 and AL-516 will also be presented.
“Janssen has an extensive and ongoing clinical trial programm for hepatitis C, including confirmatory and new exploratory studies, and we look forward to sharing these results,” said Gaston Picchio, hepatitis disease area leader, Janssen.
More articles on GI/endoscopy:
U.S. gastrointestinal endoscopic devices market: 5 key trends
US Endoscopy releases Histolock Resection Device
Dr. William Tremaine to chair University of Minnesota research reform team
